Apex Biotechnology Corp. (TPE:1733)
Taiwan
· Delayed Price · Currency is TWD 28.70
0.00 (0.00%)
Apr 29, 2026, 1:30 PM CST
Apex Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,945 | 1,852 | 1,677 | 2,244 | 2,132 | Upgrade
|
| Revenue Growth (YoY) | 5.00% | 10.48% | -25.29% | 5.28% | 6.30% | Upgrade
|
| Cost of Revenue | 1,406 | 1,331 | 1,145 | 1,667 | 1,560 | Upgrade
|
| Gross Profit | 538.74 | 521.34 | 531.12 | 576.84 | 571.51 | Upgrade
|
| Selling, General & Admin | 234.33 | 231.31 | 224.26 | 234.83 | 216.77 | Upgrade
|
| Research & Development | 149.37 | 161.52 | 163.33 | 165.45 | 153.29 | Upgrade
|
| Operating Expenses | 398.02 | 392.88 | 389.4 | 400.28 | 366.56 | Upgrade
|
| Operating Income | 140.73 | 128.46 | 141.72 | 176.56 | 204.95 | Upgrade
|
| Interest Expense | -3.39 | -3.64 | -4.39 | -5.4 | -12.53 | Upgrade
|
| Interest & Investment Income | 7.41 | 4.34 | 3.2 | 1.15 | 2.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 27.74 | 17.6 | 18.97 | 54.71 | -58.6 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.44 | 2.13 | 3.2 | 0.32 | 17.41 | Upgrade
|
| EBT Excluding Unusual Items | 174.92 | 148.9 | 162.7 | 227.35 | 153.23 | Upgrade
|
| Gain (Loss) on Sale of Investments | 14.98 | 4.23 | -3.96 | -2.89 | 31.7 | Upgrade
|
| Asset Writedown | - | - | -17.78 | -24.89 | - | Upgrade
|
| Pretax Income | 189.9 | 153.13 | 140.96 | 199.58 | 184.94 | Upgrade
|
| Income Tax Expense | 26.86 | 25.02 | 25.25 | 18.12 | -17.35 | Upgrade
|
| Earnings From Continuing Operations | 163.04 | 128.1 | 115.71 | 181.45 | 202.29 | Upgrade
|
| Minority Interest in Earnings | -0.15 | -0.11 | 0.07 | 0.33 | -0.07 | Upgrade
|
| Net Income | 162.89 | 128 | 115.78 | 181.79 | 202.22 | Upgrade
|
| Net Income to Common | 162.89 | 128 | 115.78 | 181.79 | 202.22 | Upgrade
|
| Net Income Growth | 27.26% | 10.55% | -36.31% | -10.11% | 113.33% | Upgrade
|
| Shares Outstanding (Basic) | 100 | 100 | 100 | 100 | 100 | Upgrade
|
| Shares Outstanding (Diluted) | 101 | 100 | 100 | 101 | 106 | Upgrade
|
| Shares Change (YoY) | 0.15% | 0.08% | -0.34% | -4.70% | -6.53% | Upgrade
|
| EPS (Basic) | 1.63 | 1.28 | 1.16 | 1.82 | 2.03 | Upgrade
|
| EPS (Diluted) | 1.62 | 1.27 | 1.15 | 1.81 | 1.93 | Upgrade
|
| EPS Growth | 27.56% | 10.44% | -36.46% | -6.16% | 120.97% | Upgrade
|
| Free Cash Flow | 144.86 | 300.43 | 208.48 | -9.97 | 153.28 | Upgrade
|
| Free Cash Flow Per Share | 1.44 | 2.99 | 2.08 | -0.10 | 1.45 | Upgrade
|
| Dividend Per Share | 1.300 | 1.200 | 1.100 | 1.400 | 1.300 | Upgrade
|
| Dividend Growth | 8.33% | 9.09% | -21.43% | 7.69% | 18.18% | Upgrade
|
| Gross Margin | 27.70% | 28.15% | 31.68% | 25.70% | 26.81% | Upgrade
|
| Operating Margin | 7.24% | 6.94% | 8.45% | 7.87% | 9.62% | Upgrade
|
| Profit Margin | 8.38% | 6.91% | 6.91% | 8.10% | 9.49% | Upgrade
|
| Free Cash Flow Margin | 7.45% | 16.22% | 12.44% | -0.44% | 7.19% | Upgrade
|
| EBITDA | 190.92 | 182.03 | 206.52 | 260.08 | 291.6 | Upgrade
|
| EBITDA Margin | 9.82% | 9.83% | 12.32% | 11.59% | 13.68% | Upgrade
|
| D&A For EBITDA | 50.2 | 53.56 | 64.8 | 83.52 | 86.65 | Upgrade
|
| EBIT | 140.73 | 128.46 | 141.72 | 176.56 | 204.95 | Upgrade
|
| EBIT Margin | 7.24% | 6.94% | 8.45% | 7.87% | 9.62% | Upgrade
|
| Effective Tax Rate | 14.14% | 16.34% | 17.91% | 9.08% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.